Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK

AIMS: Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are appealing as glucose‐lowering therapy for individuals with type 2 diabetes mellitus (T2DM) as they also reduce body weight and are associated with low rates of hypoglycaemia. This analysis assessed the long‐term cost‐effectiveness of semagl...

Descripción completa

Detalles Bibliográficos
Autores principales: Viljoen, Adie, Hoxer, Christina S., Johansen, Pierre, Malkin, Samuel, Hunt, Barnaby, Bain, Stephen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587509/
https://www.ncbi.nlm.nih.gov/pubmed/30362224
http://dx.doi.org/10.1111/dom.13564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587509/
https://www.ncbi.nlm.nih.gov/pubmed/30362224
http://dx.doi.org/10.1111/dom.13564

Ejemplares similares